Literature DB >> 19542626

Amyloid-beta, tau, and dementia.

Akihiko Takashima1.   

Abstract

Alzheimer's disease (AD) is clinically characterized as a progressive dementia starting with memory dysfunction and characterized pathologically as neurodegeneration accompanied by deposition of amyloid-beta, neurofibrillary tangles, and neuronal loss. AD research has endeavored to explain the clinical symptoms of AD through pathological changes and to develop various therapies for AD. Fulfillment of these goals, however, remains on the horizon. In this article, I review the relationship between neuropathological changes that occur in the brain and clinical progression of AD, and propose a hypothesis that brain aging, characterized by neurofibrillary tangles in entorhinal cortex, is pre-requisite for development of AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542626     DOI: 10.3233/JAD-2009-1090

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  21 in total

Review 1.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

2.  Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates Aβ-40 levels to presenilin 2.

Authors:  Carla A Ibrahim-Verbaas; Irina V Zorkoltseva; Najaf Amin; Maaike Schuur; Antonia M W Coppus; Aaron Isaacs; Yurii S Aulchenko; Monique M B Breteler; M Arfan Ikram; Tatiana I Axenovich; Marcel M Verbeek; John C van Swieten; Ben A Oostra; Cornelia M van Duijn
Journal:  Hum Genet       Date:  2012-08-08       Impact factor: 4.132

3.  Natural silibinin modulates amyloid precursor protein processing and amyloid-β protein clearance in APP/PS1 mice.

Authors:  Dafeng Bai; Ge Jin; Dajun Zhang; Lini Zhao; Mingyue Wang; Qiwen Zhu; Lin Zhu; Yan Sun; Xuan Liu; Xueying Chen; Liqian Zhang; Wenbo Li; Yan Cui
Journal:  J Physiol Sci       Date:  2019-05-13       Impact factor: 2.781

Review 4.  Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.

Authors:  Suzanne M de la Monte
Journal:  Eur Neuropsychopharmacol       Date:  2014-06-28       Impact factor: 4.600

Review 5.  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2012-01-01       Impact factor: 9.546

Review 6.  Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

7.  The "Alzheimer's disease signature": potential perspectives for novel biomarkers.

Authors:  Sergio Davinelli; Mariano Intrieri; Claudio Russo; Alfonso Di Costanzo; Davide Zella; Paolo Bosco; Giovanni Scapagnini
Journal:  Immun Ageing       Date:  2011-09-20       Impact factor: 6.400

Review 8.  Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

9.  Single-subject grey matter graphs in Alzheimer's disease.

Authors:  Betty M Tijms; Christiane Möller; Hugo Vrenken; Alle Meije Wink; Willem de Haan; Wiesje M van der Flier; Cornelis J Stam; Philip Scheltens; Frederik Barkhof
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

Review 10.  New treatment strategies for Alzheimer's disease: is there a hope?

Authors:  Ivan Aprahamian; Florindo Stella; Orestes V Forlenza
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.